South Korea Pharma-Biotech Space Predicted $23.2bn by 2022
South Korea has plans to invest over $1.7 billion (US) into its biotech and biopharma segments over the next five years. The pharmaceutical market in South Korea is predicted to increase to $23.2 billion (US), an increase from the $19.5 billion (US) in 2018, according to Global Data.
GlobalData’s research reveals that a number of deals within key therapy areas in South Korea’s pharma/biotech space have followed an increased trend between 2015 and 2018. The potential for biopharmaceutical development is very high in these areas, which include oncology, gastroenterology and immunology.
Phase III Trials Show Povorcitinib Significantly Improves Hidradenitis Suppurativa Outcomes
March 19th 2025In the Phase III STOP-HS1 and STOP-HS2 trials, results show that patients treated with povorcitinib for hidradenitis suppurativa experienced a ≥50% reduction in the total abscess and inflammatory nodule count.
The Misinformation Maze: Navigating Public Health in the Digital Age
March 11th 2025Jennifer Butler, chief commercial officer of Pleio, discusses misinformation's threat to public health, where patients are turning for trustworthy health information, the industry's pivot to peer-to-patient strategies to educate patients, and more.
Navigating Distrust: Pharma in the Age of Social Media
February 18th 2025Ian Baer, Founder and CEO of Sooth, discusses how the growing distrust in social media will impact industry marketing strategies and the relationships between pharmaceutical companies and the patients they aim to serve. He also explains dark social, how to combat misinformation, closing the trust gap, and more.
